Incyte Corporation (INCY)
Incyte (INCY) Beats Q1 Earnings and Revenue Estimates
Incyte (INCY) came out with quarterly earnings of $1.81 per share, beating the Zacks Consensus Estimate of $1.38 per share. This compares to earnings of $1.16 per share a year ago.
Incyte Gears Up to Report Q1 Earnings: What Can Investors Expect?
INCY heads into Q1 earnings with a $1.23 billion revenue view, driven by Jakafi, Opzelura, rising royalties and multiple new launches contributing to revenues.
Incyte Q1 Preview: The Growth Story Remains Intact
Incyte Corporation remains a Buy despite an 8% stock decline, with a widened undervaluation and a robust non-Jakafi growth story. INCY's aggressive reinvestment supports four major product launches in 2026–2027, aiming to offset Jakafi's 2028 patent cliff. Pipeline catalysts include Jakafi XR, Opzelura EU launch, Monjuvi in 1L DLBCL, and povorcitinib in HS, with management targeting $1B+ new franchise potential.
31,459 Shares in Incyte Corporation $INCY Bought by CPC Advisors LLC
CPC Advisors LLC bought a new position in shares of Incyte Corporation (NASDAQ: INCY) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 31,459 shares of the biopharmaceutical company's stock, valued at approximately $3,107,000. A number of other institutional investors
Incyte (INCY) Reports Next Week: Wall Street Expects Earnings Growth
Incyte (INCY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why Incyte (INCY) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Incyte Reports Strong 54-Week Data From Late-Stage Skin Disorder Study
Incyte's povorcitinib shows sustained 54-week efficacy in HS, with strong response rates and safety profile, reinforcing its potential.
Incyte's skin disease drug shows long-term symptom relief in late-stage trials
Incyte said on Saturday its experimental skin disease drug showed long-term reduction of symptoms in two late-stage trials.
Incyte: An Undervalued Healthcare Gem
Incyte is proactively addressing Jakafi's 2028 patent cliff through robust pipeline diversification and strategic acquisitions. Jakafi delivered $3.09B in 2025 sales, up 11% YoY, underpinning strong operational performance and funding for R&D. Opzelura posted 33% YoY growth with $678M in 2025 sales, highlighting successful portfolio expansion.
Incyte: Valued Like A Single-Drug Company Despite Diversifying Revenue
Incyte is undervalued due to overemphasis on Jakafi's 2028 US patent cliff, despite a diversifying revenue base and robust pipeline. Non-Jakafi segments grew over 50% YoY in 2025, with management guiding these products to reach $3–4B by 2030, supporting long-term growth. Consensus models an aggressive revenue and EPS decline post-cliff, but slower erosion, pipeline launches, and cost flexibility could materially soften the impact.
Glenmede Investment Management LP Has $53.58 Million Stock Position in Incyte Corporation $INCY
Glenmede Investment Management LP lifted its position in Incyte Corporation (NASDAQ: INCY) by 1.2% during the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 631,785 shares of the biopharmaceutical company's stock after acquiring an additional 7,356 shares during the
Incyte (INCY) Down 4.2% Since Last Earnings Report: Can It Rebound?
Incyte (INCY) reported earnings 30 days ago. What's next for the stock?
